| Year |
Citation |
Score |
| 2018 |
Virostko J, Hainline A, Kang H, Arlinghaus LR, Abramson RG, Barnes SL, Blume JD, Avery S, Patt D, Goodgame B, Yankeelov TE, Sorace AG. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. Journal of Medical Imaging (Bellingham, Wash.). 5: 011011. PMID 29201942 DOI: 10.1117/1.Jmi.5.1.011011 |
0.308 |
|
| 2012 |
Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 263: 663-72. PMID 22623692 DOI: 10.1148/Radiol.12110748 |
0.307 |
|
| 2010 |
Berg WA, Blume JD, Adams AM, Jong RA, Barr RG, Lehrer DE, Pisano ED, Evans WP, Mahoney MC, Hovanessian Larsen L, Gabrielli GJ, Mendelson EB. Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology. 254: 79-87. PMID 20032143 DOI: 10.1148/Radiol.2541090953 |
0.304 |
|
| 2009 |
Hylton N, Blume J, Gatsonis C, Gomez R, Bernreuter W, Pisano E, Rosen M, Marques H, Esserman L, Schnall M. MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 529. PMID 27960680 DOI: 10.1200/Jco.2009.27.15_Suppl.529 |
0.317 |
|
| 1996 |
Blume J, Piantadosi S, Royall R. A61 Likelihood analysis of sequential trials Controlled Clinical Trials. 17: S73. DOI: 10.1016/0197-2456(96)84592-2 |
0.561 |
|
| Show low-probability matches. |